5AM Opportunities II, L.P. bought $10.0M of CAMP4 THERAPEUTICS (CAMP)
Executed Oct 15 2024, disclosed Oct 15 2024, the same day.
Over the 21 trading sessions from the disclosed entry session (Oct 15 2024), the stock returned +20.8% (delay-adjusted); from the execution session (Oct 15 2024), +20.8%. Derived: entry at the session's open, exit at the close 20 sessions later.
5AM Opportunities II, L.P. (10% owner) filed 1 Form 4 report as a reporting entity in the past 24 months (1 purchase, 0 sales), most often in CAMP4 THERAPEUTICS CORPORATION (CAMP). Across 1 priced purchase filing, the average 21-session return was +20.8% from execution and +20.8% from disclosure (delay-adjusted; derived). The largest single filing was $10.0M of CAMP (909,090 sh × $11.00, as filed), executed Oct 15 2024.
Healthcare · Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→